SBSPAS-D Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
SBSPAS-D
Drotaverine Hydrochloride 80mg + Mefenamic Acid 250mg
SBSPAS-D (Drotaverine Hydrochloride 80mg + Mefenamic Acid 250mg) is manufactured under strict WHO-GMP compliance for maximum bioavailability and therapeutic efficacy.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
The active pharmacological principles in SBSPAS-D deliver targeted therapeutic action through standardized systemic bioavailability and verified pharmacodynamics.
As directed by the registered medical practitioner. Strictly adhere to full course duration.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store below 25°C in a dry place. Protect from moisture and direct sunlight.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
SBSPAS-D features Drotaverine Hydrochloride 80mg + Mefenamic Acid 250mg prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
Supplied across our regional networ for SBSPAS-D
SBSPAS-D has been supplied across our regional network of licensed retail pharmacies, showing steady clinical recovery across diverse patient age groups in routine care. Clean blister seals and break-resistant packaging prevent any in-transit leakage or product dusting. Provides an ideal balance of therapeutic efficacy, affordable pricing, and supply reliability.
Questions Regarding SBSPAS-D
What is the therapeutic indication and composition of SBSPAS-D?
SBSPAS-D contains Drotaverine Hydrochloride 80mg + Mefenamic Acid 250mg indicated for Indicated for therapeutic management within specified clinical indications under qualified physician guidance. as formulated by Sygnus Biotech.
What packaging presentations are available for SBSPAS-D?
SBSPAS-D is supplied in tamper-evident 10 x 10 Alu-Alu / Blister Pack, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for SBSPAS-D?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for SBSPAS-D along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
SBSPAS-D is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.
Related Formulations in Tablet
View all Tablet →
DAIBET-G2 V
Glimepiride 2mg + Metformin Hydrochloride 500mg + Voglibose 0.2mg Bilayered
